JP2012136519A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136519A5
JP2012136519A5 JP2012004674A JP2012004674A JP2012136519A5 JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5 JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5
Authority
JP
Japan
Prior art keywords
antibody
domain
structures
terminal side
spacer polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012004674A
Other languages
English (en)
Japanese (ja)
Other versions
JP5901299B2 (ja
JP2012136519A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012004674A priority Critical patent/JP5901299B2/ja
Priority claimed from JP2012004674A external-priority patent/JP5901299B2/ja
Publication of JP2012136519A publication Critical patent/JP2012136519A/ja
Publication of JP2012136519A5 publication Critical patent/JP2012136519A5/ja
Application granted granted Critical
Publication of JP5901299B2 publication Critical patent/JP5901299B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012004674A 2006-03-03 2012-01-13 生物活性を強化した抗体改変体 Expired - Fee Related JP5901299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012004674A JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006057475 2006-03-03
JP2006057475 2006-03-03
JP2012004674A JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008502861A Division JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Publications (3)

Publication Number Publication Date
JP2012136519A JP2012136519A (ja) 2012-07-19
JP2012136519A5 true JP2012136519A5 (cg-RX-API-DMAC7.html) 2013-05-30
JP5901299B2 JP5901299B2 (ja) 2016-04-06

Family

ID=38459178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008502861A Expired - Fee Related JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体
JP2012004674A Expired - Fee Related JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008502861A Expired - Fee Related JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Country Status (6)

Country Link
US (2) US20090304715A1 (cg-RX-API-DMAC7.html)
EP (2) EP2006305B1 (cg-RX-API-DMAC7.html)
JP (2) JP5598894B2 (cg-RX-API-DMAC7.html)
CA (1) CA2638804C (cg-RX-API-DMAC7.html)
ES (1) ES2602439T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007100083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010065578A2 (en) * 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
WO2012002562A1 (en) * 2010-06-30 2012-01-05 Tokyo University Of Science Educational Foundation Administrative Organization Modified protein therapeutics
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
AR085404A1 (es) * 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
US9683044B2 (en) * 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
MX2015009819A (es) 2013-01-28 2015-10-29 Evec Inc Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
WO2015005960A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation Removal of fragments from a sample containing a target protein using activated carbon
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
WO2017019729A1 (en) 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
WO2018129397A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
CN119421953A (zh) 2022-01-28 2025-02-11 株式会社伊贝克 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
DE3908834A1 (de) 1989-03-17 1990-09-20 Hollingsworth Gmbh Vorrichtung zur ausscheidung von verunreinigungen eines faserverbandes an einer karde
AU2002250293B2 (en) * 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities

Similar Documents

Publication Publication Date Title
JP2012136519A5 (cg-RX-API-DMAC7.html)
PH12013502568B1 (en) Anti-psgl-1 antibodies and uses thereof
JP2012116856A5 (cg-RX-API-DMAC7.html)
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
HRP20211594T1 (hr) Anti-pd1 protutijela i načini uporabe
JP2014526898A5 (cg-RX-API-DMAC7.html)
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
JP2014205674A5 (cg-RX-API-DMAC7.html)
JP2012254083A5 (cg-RX-API-DMAC7.html)
JP2012034692A5 (cg-RX-API-DMAC7.html)
HRP20221141T1 (hr) Anti-lag3 protutijela
HRP20201600T1 (hr) Anti-pd-1 antitijelo i njegova uporaba
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
WO2013095738A3 (en) Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
HRP20161298T1 (hr) Novi antagonisti protutijela i njihovi fab fragmenti protiv gpvi i njihova uporaba
JP2014240385A5 (cg-RX-API-DMAC7.html)
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
PH12013502201A1 (en) Anti-b7-h3 antibody
SG178886A1 (en) Humanized anti-cdcp1 antibodies
JP2013241409A5 (cg-RX-API-DMAC7.html)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2013513383A5 (cg-RX-API-DMAC7.html)